Back

Prolonged dual antiplatelet therapy in an extended Phase 3 Cardiac Rehabilitation Program following myocardial infarction

1 September 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Secondary prevention: a multifactorial approach Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hector Manuel Merenciano Gonzalez

Instituto de Investigacion Sanitaria INCLIVA, Valencia (Spain)

9 More presentations in this session

Presentation thumbnail
Comprehensive risk factor management through a dedicated secondary prevention clinic: experience from hamilton, Ontario
Miss C. Frketich (Hamilton, CA)
Abstract Slides Video
Presentation thumbnail
Variability of pre-test probability for obstructive coronary artery disease between referring primary care physicians and estimations from the referral letters
Mr E. Stertman (Linkoping, SE)
Abstract Slides Video
Presentation thumbnail
Integrated care using the ABC-stroke pathway improves cardiovascular outcomes and survival in patients with recent ischaemic stroke: a population-based cohort study
Doctor S. Choi (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Long-term continuation to pharmacological treatment for secondary prevention after a myocardial infarction: a register study
Ms M. Sakalaki (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
National dispensing of evidence-based treatment for New Zealand patients before and after peripheral arterial or percutaneous coronary procedures; undertreatment in plain sight.
Associate Professor S. Wells (Auckland, NZ)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention: a multifactorial approach

The Event

Event poster

ESC Congress 2024

1 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
When should we prolong DAPT beyond 12 months?
thumbnail
Congress Presentation
Antiplatelet therapy in patients with coronary artery disease: striking the right balance
thumbnail
Congress Presentation
Following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources